Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$0.98 and traded as high as C$1.43. Oncolytics Biotech shares last traded at C$1.39, with a volume of 175,816 shares.
Analysts Set New Price Targets
Several analysts have recently commented on the company. Jones Trading downgraded Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th. Lake Street Capital raised Oncolytics Biotech to a "strong-buy" rating in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of C$3.50.
Get Our Latest Stock Analysis on Oncolytics Biotech
Oncolytics Biotech Stock Performance
The business has a fifty day moving average of C$1.69 and a 200-day moving average of C$1.11. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The company has a market cap of C$1.43 billion, a PE ratio of -51.82 and a beta of 1.35.
Insider Activity at Oncolytics Biotech
In related news, Senior Officer Andrew P. Aromando bought 25,500 shares of the firm's stock in a transaction on Tuesday, July 15th. The stock was acquired at an average cost of C$1.62 per share, for a total transaction of C$41,425.92. Also, Senior Officer Jared Ryan Kelly bought 50,400 shares of the firm's stock in a transaction on Wednesday, July 16th. The shares were bought at an average price of C$1.63 per share, with a total value of C$82,284.50. In the last three months, insiders have acquired 108,300 shares of company stock valued at $178,192. 3.82% of the stock is owned by corporate insiders.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
